A Phase Ib, Multicenter, Open-label Study of HCD122 Administered Intravenously in Combination With Bendamustine in Patients With CD40+ Follicular Lymphoma Who Are Refractory to Rituximab

Inclusion Criteria:

- Confirmed diagnosis of follicular lymphoma, according to the Revised European
American Lymphoma/World Health Organization [REAL/WHO] classification

- Documented CD40+ follicular lymphoma

- Measurable lesion

- Refractory to rituximab

- Prior treatment with at least 1 chemotherapeutic regimen

- 18 years or older

- WHO Performance Status grade 0, 1, or 2

- Life expectancy > 3 months

- Obtained written informed consent

Exclusion Criteria:

- Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed
to aggressive lymphoma (i.e. DLBCL)

- History of another primary malignancy that is currently clinically significant or
currently requires active intervention

- Prior allogeneic stem cell transplantation

- Prior anaphylactic or other severe infusion reaction such that the patient is unable
to tolerate human immunoglobulin or monoclonal antibody administration

- Impaired cardiac function or clinically significant cardiac disease

- History of acute or chronic pancreatitis, surgery of the pancreas, or any risk
factors that may increase the risk of pancreatitis

- History of an active infection (viral, bacterial, or fungal) requiring systemic
therapy within 28 days before study treatment.

- Known diagnosis of human immunodeficiency virus (HIV) infection

- Evidence of previous hepatitis viral infection such as hepatitis B or hepatitis C

- Ongoing corticosteroid use (>10 mg/day prednisone or equivalent)

- Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply